Cantargia is a Swedish biotechnology company that specializes in the development of pharmaceuticals for various types of cancer and inflammatory/autoimmune diseases. Our development programme includes the candidate drugs nadunolimab (CAN04), currently in phase IIa clinical studies, and CAN10, currently in preclinical phase, as well as our discovery project CANxx. The company is listed on OMX Stockholm’s Main List (Mid Cap).
Cantargia AB was founded in 2009-2010 with the aim of refining a discovery by Professor Thoas Fioretos and Doctor Marcus Järås of Lund University. Their research showed that leukemic stem cells express a protein on their surface – IL1RAP – that is not expressed to as great a degree on normal stem cells. Further research demonstrated that this protein is also found on cancer cells from a large number of solid tumor types.
Scheelevägen 27, 22363 Lund – Sweden
|Date||Trading entity / Person||Association||Trade type||Volume|
|19.01.23||Nedjad Losic||Other||Buy||SEK 29,110.74|
|17.01.23||Göran Forsberg||Other||Buy||SEK 140,250.00|
|17.01.23||Bengt Jöndell||Other||Buy||SEK 54,665.00|
|28.07.22||Göran Forsberg||Other||Other||SEK 344,118.75|
|28.07.22||Thoas Fioretos||Other||Other||SEK 294,000.00|
|28.07.22||Bengt Jöndell||Other||Other||SEK 284,996.25|
|28.07.22||Gunnar Magnus Severus Modée Persson||Other||Other||SEK 168,660.00|
|28.07.22||Magnus Nilsson||Other||Buy||SEK 108,961.82|
|28.07.22||Liselotte Larsson||Other||Other||SEK 78,997.50|
|28.07.22||David Liberg||Other||Other||SEK 27,990.00|
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.